Editing Endothelium-derived relaxing factor (section)

{{Short description|Nitric Oxide as an EDRF}}
{{Update|date=January 2022}}[[File:Nitric-oxide-2D.png|thumb|131x131px|Nitric Oxide (NO), the principal EDRF]]
The '''Endothelium-derived relaxing factor''' ('''EDRF''') is a strong [[Vasodilation|vasodilator]] produced by [[Endothelial cells|cardiac endothelial cells]] in response to stress signals such as high levels of [[ADP-ribosylation|ADP]] accumulation or [[Hypoxia (medical)|hypoxia]].{{fact|date=January 2025}} [[Robert F. Furchgott]] is widely recognised for this discovery, even going so far as to be a co-recipient of the 1998 [[Nobel Prize in Physiology or Medicine|Nobel Prize in Medicine]] with his colleagues [[Louis J. Ignarro]] and [[Ferid Murad]]. [[Nitric oxide]] (NO) is a key component in any EDRF as these compounds either include NO or are structurally in the form of NO.<ref>{{Cite journal |last1=Bauer |first1=Viktor |last2=Sotníková |first2=Ružena |date=29 December 2010 |title=Nitric oxide--the endothelium-derived relaxing factor and its role in endothelial functions |journal=General Physiology and Biophysics |volume=29 |issue=4 |pages=319–340 |doi=10.4149/gpb_2010_04_319 |issn=0231-5882 |pmid=21156995|doi-access=free }}</ref><ref name=":0">{{Cite journal |last1=Francis |first1=S. H. |last2=Busch |first2=J. L. |last3=Corbin |first3=J. D. |date=2010-09-01 |title=cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action |journal=Pharmacological Reviews |language=en |volume=62 |issue=3 |pages=525–563 |doi=10.1124/pr.110.002907 |issn=0031-6997 |pmc=2964902 |pmid=20716671}}</ref>